Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in active psoriatic arthritis
NCT03881059Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in psoriatic arthritis (PsA) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: American College of Rheumatology 20 Response at 16 weeks. Started Apr 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03881059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881059.